Bahl & Gaynor Inc. Has $46.48 Million Stake in Perrigo Company plc $PRGO

Bahl & Gaynor Inc. increased its position in Perrigo Company plc (NYSE:PRGO) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,087,075 shares of the company’s stock after purchasing an additional 107,774 shares during the quarter. Bahl & Gaynor Inc. owned approximately 1.52% of Perrigo worth $46,479,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PRGO. Norges Bank bought a new position in shares of Perrigo during the 2nd quarter worth about $36,755,000. Perpetual Ltd boosted its holdings in Perrigo by 64.2% during the third quarter. Perpetual Ltd now owns 3,149,878 shares of the company’s stock valued at $70,148,000 after purchasing an additional 1,231,400 shares in the last quarter. Ion Asset Management Ltd. grew its stake in shares of Perrigo by 34.7% in the 2nd quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock valued at $102,007,000 after purchasing an additional 983,727 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Perrigo by 126.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after buying an additional 647,982 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Perrigo by 9.5% during the 2nd quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after buying an additional 637,678 shares during the period. Institutional investors own 95.91% of the company’s stock.

Key Headlines Impacting Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Analyst support remains: Canaccord trimmed its price target from $20 to $17 but kept a “buy” rating, signaling some analysts still see upside versus the current share level. Canaccord price target note (Benzinga)
• Positive Sentiment: Company execution items: Perrigo says FY2025 adjusted EPS landed at the midpoint of its updated outlook, advanced a “3‑S” commercial plan, gained share in OTC/store‑brand categories, and launched operational savings expected to deliver $80–$100M pre‑tax annualized — all items that support longer‑term margin recovery. PR Newswire: FY2025 results & initiatives
• Neutral Sentiment: Analyst/investor materials available — full earnings call transcript and slide deck were published for investors who want details on segment reporting changes and management commentary. Reviewing these can help assess whether guidance and the formula exposure are temporary. Earnings call transcript/highlights (Yahoo)
• Negative Sentiment: Q4 miss on EPS: Perrigo reported $0.77 EPS vs. consensus ~$0.80 and EPS is down year‑over‑year (prior $0.93), which eroded near‑term investor confidence despite a slight revenue beat. Zacks: Q4 earnings miss & analysis
• Negative Sentiment: Weaker FY2026 outlook: Management set FY2026 EPS guidance at $2.25–$2.55 (below the ~$2.70 consensus) and reiterated revenue guidance below/at consensus, explicitly calling out Infant Formula as a drag and introducing a ‘CORE’ view that excludes formula/divestitures — the guidance shortfall and exposed category risk are the main reasons the stock is down. Zacks: weak 2026 guidance & formula headwinds

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Argus upgraded Perrigo to a “hold” rating in a research report on Wednesday, January 14th. JPMorgan Chase & Co. lowered their target price on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Canaccord Genuity Group cut their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday. Wall Street Zen cut shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Perrigo presently has an average rating of “Hold” and an average price target of $19.33.

Perrigo Price Performance

Perrigo stock opened at $13.23 on Monday. The business’s 50-day simple moving average is $14.41 and its 200 day simple moving average is $17.41. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -1.29, a P/E/G ratio of 1.30 and a beta of 0.41. Perrigo Company plc has a 12-month low of $12.17 and a 12-month high of $30.93.

Perrigo (NYSE:PRGO) last released its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the company posted $0.93 earnings per share. The business’s revenue for the quarter was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, research analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd will be given a dividend of $0.29 per share. The ex-dividend date is Monday, March 2nd. This represents a $1.16 annualized dividend and a dividend yield of 8.8%. Perrigo’s payout ratio is presently -11.28%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.